Literature DB >> 884004

The effect of treatment with clofibrate on hepatic triglyceride and lipoprotein lipase activities of post heparin plasma in male patients with hyperlipoproteinemia.

J Boberg, M Boberg, R Gross, S Grundy, J Augustin, V Brown.   

Abstract

Twelve male patients with hyperlipoproteinemia were treated with clofibrate, 1 g twice daily. Serum triglyceride concentration decreased on the average 28 +/- 6%. No significant change of serum cholesterol concentration occurred. Post heparin plasma lipoprotein lipase activity isolated and partially purified by heparin Sepharose affinity chromatography was determined quantitatively. During the clofibrate treatment this enzyme activity increased 48 +/- 9%. The post heparin hepatic triglyceride lipase did not change significantly. The possibility that the serum triglyceride-lowering effect of clofibrate might partly be explained by an increased removal rate of triglyceride rich lipoproteins through increased lipoprotein lipase activity is discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 884004     DOI: 10.1016/0021-9150(77)90168-x

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  Role of lipoprotein lipase in the regulation of high density lipoprotein apolipoprotein metabolism. Studies in normal and lipoprotein lipase-inhibited monkeys.

Authors:  I J Goldberg; W S Blaner; T M Vanni; M Moukides; R Ramakrishnan
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

Review 2.  Managing elevated blood lipid concentrations. Who, when and how?

Authors:  A M Dart
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

3.  Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects.

Authors:  F Heller; C Harvengt
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 4.  Lipid-lowering drugs. An overview of indications and optimum therapeutic use.

Authors:  D R Illingworth
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

5.  A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family.

Authors:  G Franceschini; C R Sirtori; A Capurso; K H Weisgraber; R W Mahley
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

6.  Magnesium pyridoxal 5-phosphate glutamate reduces hyperlipidaemia in patients with chronic renal insufficiency.

Authors:  R Kirsten; B Heintz; K Nelson; H G Sieberth; G Oremek; J Hasford; U Speck
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.